替罗非班在急性心肌梗死介入治疗中的临床研究

目的观察急性心肌梗死(AMI)患者经皮行冠状动脉介入治疗(PCI)时替罗非班的有效性及安全性。方法 80例已确诊的AMI患者PCI术前随机分为替罗非班组和对照组,观察两组PCI术后即刻梗死相关动脉肌梗死溶栓心肌组织灌注(TMP)分级情况、24 h及30 d内主要不良心脏事件(MACE)发生率、出血事件发生率。结果替罗非班组TMP3级发生率高于对照组,24 h及30 d内MACE发生率低于对照组,差异有统计学意义(P<0.05);替罗非班组出血事件发生率高于对照组,但差异无统计学意义(P>0.05)。结论替罗非班能够改善心肌组织再灌注,减少不良心脏事件,疗效优于常规治疗,可安全用于AMI介入治疗中。

Efficacy and Safety of Tirofiban for Percutancous Coronary Intervention in Patients with Acute Myocardial Lnfarction

Objective To evaluate the efficacy and safety of tirofiban for percutaneous coronary intervention in patientswith acute myocardial infarction.Methods 80 patients diagnosed AMI were randomly divided into study group(n=40)and the control group(n=40).The coronary TMP flow of IRA after PCI,major adverse cardiac events(MACE)rates within 24 hours and 30 days,bleeding rates were analyzed and compared between the two groups.Results Compared with control group,the patients treated with tirofiban were significantly better TIMI3 flow degree(P<0.05)The tirofiban group decreased MACE in 24 hours and 30 days after PCI(P<0.05).The complication of bleeding rate showed higher in the tirofiban group,but there was not statistical significant in between two groups(P>0.05).Conclusion The results suggest that tirofiban is a safe and moreefficacious therapy for the patients with AMI during PCI compared with conventional therapy,which can improve the situation of myocardial reperfusion and degree the MACE.